Thinking beyond the Aducanumab Controversy.

Abstract

Annals of NeurologyVolume 90, Issue 6 p. 1003-1004 Letters/Replies Thinking beyond the Aducanumab Controversy Khalid Iqbal PhD, Corresponding Author Khalid Iqbal PhD khalid.iqbal.ibr@gmail.com orcid.org/0000-0002-7670-9580 Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY Address correspondence to Dr Iqbal, Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314. E-mail: khalid.iqbal.ibr@gmail.comSearch for more papers by this author Khalid Iqbal PhD, Corresponding Author Khalid Iqbal PhD khalid.iqbal.ibr@gmail.com orcid.org/0000-0002-7670-9580 Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY Address correspondence to Dr Iqbal, Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314. E-mail: khalid.iqbal.ibr@gmail.comSearch for more papers by this author First published: 22 October 2021 https://doi.org/10.1002/ana.26252Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume90, Issue6December 2021Pages 1003-1004 RelatedInformation